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Introduction. Leptin as an adipose-tissue-related peptide hormone contributes to the control of food intake, energy expenditure,
and other activities such as cell proliferation. Therefore, association of leptin level with thyroid cancer has been suggested recently.
Considering that thyroid cancer is the most common endocrine cancer, the aim of this study was evaluation of leptin levels in
thyroid cancer. Materials and Methods. 83 patients with papillary thyroid cancer (35 males and 48 females) with 90 healthy persons
as control group (40 male and 50 females) were selected. serum thyroxine, thyrotropin, and leptin levels were determined in both
groups. As a body fat tissue aﬀects leptin level, so height and weight were measured and body mass index was calculated too.
Results. There was no statistically signiﬁcant diﬀerence in age, serum Thyroxine, and Thyrotropin levels. BMI in women was more
than in men in both groups. Serum leptin levels in thyroid cancer group were signiﬁcantly higher than control group (P<0.05).
Conclusion. The results of this study showed an acceptable association between the hormone Leptin levels with papillary thyroid
cancer, so it may be considerad as a correlated peptide which may help in the diagnosis or conﬁrmation of thyroid cancer beside
in other speciﬁc tumor markers.
1.Introduction
leptin with 16kDa molecular weight mainly produces by
white adipose tissue cells [1]. So its level is proportional
to the adipose tissue mass [2]. leptin as a neuroendocrine
hormone has eﬀects on the glucose metabolism, sexual
maturation, reproduction, pituitary-adrenal axis, immune
system, thyroid, and growth hormones level [3–6]. The
association between this neuroendocrine hormone with
obesity and some cancers has been proposed. Probably
this hormone is an important risk factor in carcinogenesis,
because obesity itself can promote tumorgenesis and is a risk
factor for cancer over time [7, 8]. On the other hand, leptin
plays an important role in the oxidation reactions such as
fatty acid oxidation [9] and angiogenesis [10]. There are
many reports concerning the eﬀect of leptin on stimulation
of cell mitosis and its involvement in carcinogenic stages
of breast, clone, prostate, lung, kidney, and ovary cells
[11–16]. Studies have shown that leptin by increase of cell
proliferation and inhibition of apoptosis is involved in
creating certain types of tumors [17–19].
leptin acts through its receptor on the cell surface
and its receptor expression also increases following the
activity of PI3K/AKT pathway and increases the activity of
antiapoptosis molecules such as Bcl-XL and XIAP [20]. In
some cancer cells, expression of leptin receptor levels and
stimulation by leptin will lead to increase of cell proliferation
[21]. leptin stimulates expression of some molecules such
as CyclinD1, CDK2 and c-Myc that result in cell cycle
progression and cell proliferation [21, 22].
The Important molecular pathways, such as JAK/STAT3,
PI3K/AKT, ERK/MAPK, in many cancer cells can be acti-
vated by leptin/leptin receptors [21–24]. Furthermore, leptin
with the induction of VEGF and VEGF-R2 molecules
expression plays an important role in the tumorigenesis
[25]. These molecules are involved in many malignancies
such as colon, stomach, endometrial, ovarian, and breast
cancer [26–30]. Additionally, increased serum levels of2 Journal of Thyroid Research
leptin and its receptor have been associated with distant
metastases, disease recurrence, and lower survival in patients
with breast cancer [31]. Increased expression of leptin and
its receptor in papillary thyroid cancer has been proved.
This hormone probably through its receptor and activation
of the PI3K/AKT pathway plays an important role in
papillary thyroid cancer pathogenesis. It also seems that the
oncogenic eﬀects of leptin on papillary thyroid carcinoma
cells are related to the stimulating cell proliferation and
apoptosis inhibition. Involvement of thyroid hormones on
basal metabolism and regulating appetite and weight control
in many scientiﬁc reports is given explicitly [10, 32–34]. The
most common endocrine malignancy is thyroid cancer, and
papillary form of thyroid cancer is the most common type
of thyroid cancer (80–90%) [32] .T h ea i mo ft h i ss t u d yw a s
determining theserumleptin levelsin patientswithpapillary
thyroid cancer and its comparison with healthy subjects.
2.MaterialsandMethods
2.1. Subjects
Patients. The case population consisted of 83 individuals,
including 35 males and 48 females, 14 to 62 years (mean
age 38.6 years) with papillary thyroid cancer (PTC). They
were referred to Research Institute for Endocrine Sciences,
Shahid Beheshti University of Medical Science. Also, 90
persons were selected as control group (40 male and 50
females) from referred to the laboratory with normal thyroid
function tests (TSH: 0.3 = 3.5mIU/L, T4: 4.5 = 12.5μg/dL,
T = Up: 25 = 35% and T3: 75 = 210ng/mL) with age,
sex, BMI matched with case group. Both groups were also
matched for age and sex. The participants were included
in the survey after obtaining an informed consent. Also,
the clinical examination was performed by endocrinologist.
The diagnosis of PTC was conﬁrmed by histopathologic
documents. This study has been approved by Institutional
Review Board and Ethics Committee of Obesity Research
Center, Research Institute for Endocrine Sciences, Shahid
Beheshti University of Medical Sciences.
2.2. Methods. Blood sampling was performed in both stud-
ied groups. For preparation of serum, 3mL of whole blood
was collected from antecubital vein in sitting position and
was incubated 10min in RT for coagulation. Then sera
separated by 10min centrifugation at 3000rpm and the
obtained sera were aliquoted in three 0.5mL microtubes.
Theisolatedserumsamplesfromeachindividualwerestored
in 1mL Eppendorf microtubes at −80◦C( J a p a n ’ sS a n y oC
Company).
Anthropometric characteristics, including height and
weight of patients and control group, were measured by
height measuring scaled balance (Seca, German company);
height with 0.5cm and weight with 250g sensitivity were
reported. These data were used to calculate the body mass
index (kg/m2). Demographic proﬁles, including age, and sex
were also recorded. Those individuals, who were using drugs
aﬀecting thyroid function and obesity drugs, were excluded.
In groups thyroxine, thyrotropin, and leptin hormones
were measured by ELISA method. The used kits were
prepared from the Canadian company (DBC Company,
Ontario, Canada). The ELISA reader was from Tecan
Austrian Company and Sunrise Model. Human thyrotropin
and leptin hormones were determined based on sandwich
ELISA method, whereas a thyroxin hormone was measured
according to the competitive EIA method. The sensitivity
of thyroxine, thyrotropin, and leptin kits was 0.6μg/dL,
0.1mU/L, and 0.4ng/mL, respectively. Additionally, the
coeﬃcientsofvariationfortheseassayswere6.2%,7.1%,and
6.5%, respectively.
2.2.1. Statistical Analysis. According to the normal distri-
bution of data obtained by testing Kolmogorov-Smirnov
(KS) (P = 0.68 for case group and P = 0.52 for
control group), the frequency, mean and standard deviation
were used to describe characteristics. All the data were in
normal distribution (except leptin after normalization). The
independent t-test was used to compare mean (except leptin
with geometric mean and CI 95%) of variables between
two groups. Comparison of qualitative data was done with
Chi-square test. Further, data was analyzed using statistical
software (SPSS 15), and signiﬁcant level was considered at
0.05.
3. Results
Demographic proﬁles and anthropometric characteristics of
participants are provided in Table 1. The results of thyroid
hormones test, including thyroxine and thyrotropin in both
control and patients groups, are given in Table 2. Since the
leptin hormone secreted from adipose tissue is diﬀerent in
male and female, therefore the diﬀerent levels of measured
leptin hormone in two groups are shown in Table 3 (gender
based). Height, weight, and body mass index between males
and females of both groups were signiﬁcant (P<0.05). In
addition, a signiﬁcant diﬀerence (P<0.05) was observed
between the leptin hormone levels in males and females
in both healthy and cancer groups. The amount of leptin
hormone in cancer patients was higher than that in normal
individuals, signiﬁcantly (P<0.05).
4. Discussion
Our data showed that the serum leptin levels of Iranian
patients with papillary thyroid carcinoma were signiﬁcantly
higher than those in control group subjects. This increased
level was observed in both males and females with papillary
thyroid carcinoma. As this increased level was observed in
both gender and diﬀerent ages, so it could be related to
thyroid carcinoma and it is independent of sex and age.
Even though in this study the leptin level was higher in
females than males in both groups, this is probably related
to more adipose tissue mass in women. Both leptin and
thyroid hormones cause thermogenesis and reduce body
weight therefore maybe it is considered as a ﬁrst association
between the two hormones. The hunger reduces the leptinJournal of Thyroid Research 3
Table 1: Anthropometric characteristics of participants.
Group Sex Height (cm) Weight (kg) BMI (kg/m2) Mean age (year)
Control Female (50) 159.5 ± 12.1 61.9 ± 0.3 24.5 ± 2.3 38.1 ± 12.5
Male (40) 169.2 ± 10.5 66.3 ± 0.2 23.2 ± 2.0 37.9 ± 15.8
Case Female (48) 160.2 ± 11.6 63.7 ± 0.3 24.9 ± 2.7 39.1 ± 13.7
Male (35) 170.4 ± 11.3 68.4 ± 0.2 23.7 ± 2.4 37.5 ± 17.0
Table 2: Serum levels of thyroxin and thyrotropin hormones in
participants.
Group Thyroxin (μg/dL) Thyrotropin (mU/L)
Control 9.1 ± 2.9 2.4 ± 1.2
Case 8.9 ± 3.0 2.6 ± 1.0
Table 3: Serum leptin levels in participants.
Group
Females serum
leptin level
(ng/mL)
Males serum leptin
level (ng/mL)
Control 4.3 ± 6.9 2.2 ± 5.6
Case 19.6 ± 23.3
(P<0.05)
10.4 ± 17.3
(P<0.05)
and thyroid hormones levels [35]. High levels of thyroid
hormones decrease leptin expression in adipose tissue. But
the most studies have not shown signiﬁcant changes in leptin
levels in hypothyroidism and hyperthyroidism disorders [36,
37].However,increasedleptinlevelinpostpartumthyroiditis
has been reported [38]. Akinci et al. reported that leptin
levels increased in papillary thyroid carcinoma in Turkish
population [39]. But in their study only 34 cases were
investigated, the status of thyroid function in patients and
healthy group was not evaluated, and age-matching was not
considered [39]. In our study, 83 persons were matched for
age, sex, and BMI. Assessing thyroid function in patients
and healthy individuals was performed, and no signiﬁcant
diﬀerence was observed in both groups.
In both above studies, BMI in women was higher than
in men, which was quite predictable. In both studies leptin
levels in women were higher than those in men that is
because of increased fat mass in women. In one study
Cheng et al. showed that expression of leptin and/or leptin
receptor in papillary thyroid cancer was associated with
neoplasm aggressiveness, including tumor size and lymph
node metastasis [40]. Interestingly, in another study, Uddin
et al. demonstrated that leptin plays an important role in
papillary thyroid cancer pathogenesis through PI3K/AKT
pathway via its receptor (Ob-R) and is a potential prognostic
marker associated with an aggressive phenotype and poor
survival [32].
One of the limitations of our study was inability to
followup the patients after surgery. Therefore, reduction
or normalization of high leptin levels in thyroid cancer
patients was not assessed. However, a signiﬁcant increase of
serum leptin levels in Iranian patients with papillary thyroid
carcinoma maybe used as a reliable marker to diagnose or
conﬁrm papillary thyroid cancer. In addition if the leptin
levels in cancer patients decrease after thyroidectomy, it will
be used for the followup treatment, possibly. So a before-
after study is recommended for future investigations instead
of case control study. Thus, leptin level measurement can be
used to followup the treatment of patients.
Strongly high leptin level in papillary thyroid cancer
patients in comparison with health subject potentially sug-
gests leptin as a peptide marker of papillary thyroid cancer.
It means that adipose tissue secreted hormones, proteins,
and peptides potentially may have application in diagnosis,
conﬁrmation, and/or treatment followup.
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